Navigation Links
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/3/2008

is Phase 1 trial, the Company anticipates launching a Phase 2 clinical trial with new HspE7 in patients with cervical intraepithelial neoplasia (CIN). The Company is also in discussions with clinical investigators regarding the design and implementation of a second Phase 2 trial with new HspE7 in patients that are HIV-positive with low-grade CIN.

Affiliations and investigators in this trial currently include the Montefiore Medical Center; William D. Kolton, M.D. of San Diego, California; Linda Roman, M.D. of the University of Southern California (USC); Michael L. Twede, M.D. of the Salt Lake Women's Center in Sandy, Utah; and Mark T. Saunders, M.D. at the Mt. Timpanogos Women's Healthcare/Physician's Research in Pleasant Grove, Utah.

About HspE7 + Poly-ICLC:

The Company's lead candidate, HspE7 + Poly-ICLC, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 + Poly-ICLC contains the novel CoVal(TM) fusion protein, HspE7, that is co-administered with the adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist adjuvant. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 + Poly-ICLC for multiple indications.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nven
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Boston Children,s ... benefiting from 3D printing of their anatomy before ... life-threatening cerebrovascular malformations (abnormalities in the brain,s blood ... Reporting online today in the Journal of ... of 3D printing and synthetic resins to create ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... tirofiban also edges abciximab, CHICAGO, March ... randomized,study is answering important questions about the ... patients with a type of heart,attack known ... drug-eluting stents outperformed bare-metal stents, and high-dose,tirofiban, ...
... and type, prasugrel bests clopidogrel, CHICAGO, March ... activity in patients with acute coronary syndromes (ACS) ... than half the risk of,thrombosis, or blood clotting, ... data from the Trial to Assess Improvement in ...
Cached Medicine Technology:Drug-Eluting Stents Outperform Bare Stents in Heart Attack 2Drug-Eluting Stents Outperform Bare Stents in Heart Attack 3Drug-Eluting Stents Outperform Bare Stents in Heart Attack 4TRITON-TIMI 38 Stent Analysis Favors Prasugrel 2TRITON-TIMI 38 Stent Analysis Favors Prasugrel 3
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... The ... Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders ... the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... for the Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the ... 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, inability to locate ...
(Date:7/31/2015)... ... ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 brain injury, almost slept ... equipment was set up to depict the newly poured concrete. With a clear view of ... speaks for itself. Chatfield is also a highly praised safety and drug education speaker/comedian. , ...
(Date:7/31/2015)... ... 2015 , ... Patients with higher levels of a key protein are at ... Communications and led by researchers from the Icahn School of Medicine at Mount Sinai. ... led to greater production of the related RNT1 protein, which caused kidney cells to ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
... broke his silence for the first time. Since his parents broke ... problem of substance abuse. ,He revealed that he was ... He was being treated for a number of illnesses as a ... the name of the drug that he had been using. ...
... today issued the "Critical Path Opportunities for Generic Drugs" ... impede the development of generic versions of commonly used ... Critical Path Initiative, established in 2004 to discern what ... device along the critical path from discovery, or proof ...
... but a Dartmouth discovery that a cousin of niacin prolongs ... ,The research, reported in the May 4 issue ... yeast cells, much like calorie restriction does in animals. It ... ,Radical calorie reduction can extend life. Dieting or ...
... women who took an epilepsy drug during their pregnancy are ... In question is the drug valproate (already at the ... has damaged children). Valproate seems to double the chance that ... ,Around 140 British families claim that their children are ...
... research published in the journal Proceedings of the National ... produce// an antibiotic which inhibits the work of an ... from attack. ,Although such so-called gene-for-gene interactions ... examples of a single gene in a pathogen targeting ...
... an agency of the New York state government has lashed ... Hospital// as a shameful "chamber of filth, decay, indifference and ... Union, the agency has filed a suit in the federal ... where patients are subjected to overcrowded conditions, physical abuse and ...
Cached Medicine News:Health News:Cousins Recovering from His Substance Abuse Problem 2Health News:New Critical Path Report Highlights Research Needed to Foster Generic Drug Development 2Health News:Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find 2Health News:Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find 3Health News:Anti-Epileptic Drug Intake May Result In Children With Mental Retardation 2Health News:Scientists Discover Rare ‘gene-for-gene’ Interaction That Helps Bacteria Kill Their Ho 2Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2
Freer elevator, double end, 7 1/4", S/B....
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
... absorbable gelatin sponge, U.S.P. is a ... sponge intended for hemostatic use by ... sponge is off-white and porous in ... hemostasis, highly favorable surgeon preference ratings ...
16 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: